BR112023024494A2 - Polipeptídeos engenheirados - Google Patents

Polipeptídeos engenheirados

Info

Publication number
BR112023024494A2
BR112023024494A2 BR112023024494A BR112023024494A BR112023024494A2 BR 112023024494 A2 BR112023024494 A2 BR 112023024494A2 BR 112023024494 A BR112023024494 A BR 112023024494A BR 112023024494 A BR112023024494 A BR 112023024494A BR 112023024494 A2 BR112023024494 A2 BR 112023024494A2
Authority
BR
Brazil
Prior art keywords
polypeptides
engineered polypeptides
variants
engineered
polypeptide
Prior art date
Application number
BR112023024494A
Other languages
English (en)
Portuguese (pt)
Inventor
Amalio Telenti
Davide Corti
Gyorgy Snell
Istvan Bartha
Alexander Schmid Michael
Nadine Czudnochowski
Original Assignee
Humabs Biomed Sa
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Vir Biotechnology Inc filed Critical Humabs Biomed Sa
Publication of BR112023024494A2 publication Critical patent/BR112023024494A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023024494A 2021-05-24 2022-05-23 Polipeptídeos engenheirados BR112023024494A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163192549P 2021-05-24 2021-05-24
US202163265032P 2021-12-06 2021-12-06
US202263266453P 2022-01-05 2022-01-05
PCT/US2022/030556 WO2022251119A2 (en) 2021-05-24 2022-05-23 Engineered polypeptides

Publications (1)

Publication Number Publication Date
BR112023024494A2 true BR112023024494A2 (pt) 2024-02-06

Family

ID=82156443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024494A BR112023024494A2 (pt) 2021-05-24 2022-05-23 Polipeptídeos engenheirados

Country Status (13)

Country Link
US (1) US20250296986A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347642A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024521131A (cg-RX-API-DMAC7.html)
KR (1) KR20240035758A (cg-RX-API-DMAC7.html)
AU (1) AU2022280767A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024494A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218489A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003455A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017754A2 (cg-RX-API-DMAC7.html)
IL (1) IL308509A (cg-RX-API-DMAC7.html)
MX (1) MX2023013859A (cg-RX-API-DMAC7.html)
TW (1) TW202306978A (cg-RX-API-DMAC7.html)
WO (1) WO2022251119A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183367A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
CA3183373A1 (en) 2020-07-06 2022-01-13 Gevorg GRIGORYAN Antigen binding molecules targeting sars-cov-2
KR20230058434A (ko) 2020-08-26 2023-05-03 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 SARS-CoV-2를 표적으로 하는 항원 결합 분자
WO2023230439A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
JP2025526405A (ja) 2022-07-27 2025-08-13 ヒューマブス・バイオメッド・ソシエテ・アノニム Rsv及びmpvパラミクソウイルスに対する広域中和抗体
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
TW202446788A (zh) 2023-04-10 2024-12-01 美商維爾生物科技公司 結合多種薩貝冠狀病毒之抗體
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
EP4743488A1 (en) 2023-07-13 2026-05-20 VIR Biotechnology, Inc. Antibodies widely neutralizing against paramyxoviruses RSV and MPV

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
US9663581B2 (en) 2012-04-25 2017-05-30 Momenta Pharmaceuticals, Inc. Modified glycoproteins
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
US20160257761A1 (en) * 2015-03-06 2016-09-08 Macrogenics, Inc. HER2/neu-Specific Antibodies and Methods of Using Same
US11267899B2 (en) 2015-05-13 2022-03-08 Zumutor Biologics Inc. Afucosylated protein, cell expressing said protein and associated methods
US20200157192A1 (en) * 2017-05-10 2020-05-21 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
JP7351845B2 (ja) * 2018-03-23 2023-09-27 ブリストル-マイヤーズ スクイブ カンパニー Micaおよび/またはmicbに対する抗体ならびにそれらの使用
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections

Also Published As

Publication number Publication date
WO2022251119A2 (en) 2022-12-01
AU2022280767A1 (en) 2024-01-18
EP4347642A2 (en) 2024-04-10
WO2022251119A9 (en) 2023-10-05
CL2023003455A1 (es) 2024-07-19
MX2023013859A (es) 2024-02-15
IL308509A (en) 2024-01-01
TW202306978A (zh) 2023-02-16
CO2023017754A2 (es) 2024-05-10
CA3218489A1 (en) 2022-12-01
WO2022251119A3 (en) 2023-01-12
US20250296986A1 (en) 2025-09-25
JP2024521131A (ja) 2024-05-28
KR20240035758A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
MX2023013859A (es) Polipeptidos modificados.
MY197648A (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
SA521421825B1 (ar) (glp1) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (gdf15) وعامل تمايز النمو 15 واستخدامه
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
MX2019009817A (es) Anticuerpos anti-tau y metodos de uso de los mismos.
UY40283A (es) Método para alterar una propiedad de una planta
MX2020007888A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
BRPI0807929A2 (pt) Anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, polipeptídeo isolado, composição, ácido nucleico isolado, vetor de expressão, célula hospedeira, vacina do vírus da hepatite c (hcv), kit, métodos para tratar e detectar uma infecção por vírus da hepatite c (hcv) e para identificar um anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo, e, proteína e2 recombinante do vírus da hepatite c (hcv)
BR112012006492A2 (pt) proteína de fusão de anticorpo multivalente, e, ligação de albumina
BR112023017749A2 (pt) Composições incluindo adjuvantes sbi e métodos de uso das mesmas
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
MX2008013057A (es) Proteinas de enlace que comprenden regiones bisagra y regiones fc de inmunoglobulina que tienen funciones efectoras fc alteradas.
PE20141787A1 (es) Composiciones anti-cgrp y uso de las mismas
BR112018071107A2 (pt) composições e métodos para a detecção de proteínas da célula hospedeira
GEAP202515689A (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
BRPI0408501A (pt) proteìna de ligação ao receptor nogo
PE20230348A1 (es) Variantes de anticuerpos felinos
BR112021026789A2 (pt) Sialidases humanas recombinantes, proteínas de fusão de sialidase e métodos de uso das mesmas
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
MX2019002178A (es) Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
WO2021252974A3 (en) Collagen-targeted fusion proteins and antibodies